Development, characterization and pharmacokinetics of mupirocin-loaded nanostructured lipid carriers (NLCs) for intravascular administration

Khent P. Alcantara, Mohd Hanif Zulfakar, Agnes L. Castillo

Research output: Contribution to journalArticle

Abstract

Mupirocin is a promising broad-spectrum antibiotic that is effective in treating MRSA infections. However, due to its rapid elimination and hydrolysis following injection and high protein binding, current therapeutic use is limited to topical administration. Nanotechnology-driven innovations provide hope for patients and practitioners in overcoming the problem of drug degradation by encapsulation. The objective of this research is to develop and characterize Mupirocin-Loaded Nanostructured Lipid Carriers (M-NLC) for intravascular administration. The MNLC was produced by a combination of high shear homogenization and high pressure homogenization of solid (cetyl palmitate) and liquid (caprylic/caprylic acid) biocompatible lipids in 5 different ratios. The mean particle size, polydispersity index (PDI) and the zeta potential (ZP) of the MNLC formulations were between 99.8 and 235 nm, PDI lower than 0.164, ZP from −25.96 to −19.53 and pH ranging from 6.28–6.49. The MNLC formulation also enhances the anti-bacterial activity of mupirocin. All formulation showed sustained drug release and good physical characteristics for three months storage under 25 °C. It also revealed that the MNLC 1 is safe at 250 mg/kg dose in rats. The MNLC 1 also showed a significant increase in plasma concentration in rabbits following IV administration thus, demonstrating an enhancement on its pharmacokinetic profile as compared to free mupirocin.

Original languageEnglish
Article number118705
JournalInternational Journal of Pharmaceutics
Volume571
DOIs
Publication statusPublished - 25 Nov 2019

Fingerprint

Mupirocin
Pharmacokinetics
Lipids
Topical Administration
Nanotechnology
Therapeutic Uses
Methicillin-Resistant Staphylococcus aureus
Particle Size
Protein Binding
Hydrolysis
Anti-Bacterial Agents
Rabbits
Pressure
Injections
Infection
Research
Pharmaceutical Preparations

Keywords

  • Antimicrobial
  • Intravenous administration
  • Mupirocin
  • Nanomedicine
  • Nanostructured lipid carriers

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{3bed51bac11441e8826d8a1d8368d9d4,
title = "Development, characterization and pharmacokinetics of mupirocin-loaded nanostructured lipid carriers (NLCs) for intravascular administration",
abstract = "Mupirocin is a promising broad-spectrum antibiotic that is effective in treating MRSA infections. However, due to its rapid elimination and hydrolysis following injection and high protein binding, current therapeutic use is limited to topical administration. Nanotechnology-driven innovations provide hope for patients and practitioners in overcoming the problem of drug degradation by encapsulation. The objective of this research is to develop and characterize Mupirocin-Loaded Nanostructured Lipid Carriers (M-NLC) for intravascular administration. The MNLC was produced by a combination of high shear homogenization and high pressure homogenization of solid (cetyl palmitate) and liquid (caprylic/caprylic acid) biocompatible lipids in 5 different ratios. The mean particle size, polydispersity index (PDI) and the zeta potential (ZP) of the MNLC formulations were between 99.8 and 235 nm, PDI lower than 0.164, ZP from −25.96 to −19.53 and pH ranging from 6.28–6.49. The MNLC formulation also enhances the anti-bacterial activity of mupirocin. All formulation showed sustained drug release and good physical characteristics for three months storage under 25 °C. It also revealed that the MNLC 1 is safe at 250 mg/kg dose in rats. The MNLC 1 also showed a significant increase in plasma concentration in rabbits following IV administration thus, demonstrating an enhancement on its pharmacokinetic profile as compared to free mupirocin.",
keywords = "Antimicrobial, Intravenous administration, Mupirocin, Nanomedicine, Nanostructured lipid carriers",
author = "Alcantara, {Khent P.} and Zulfakar, {Mohd Hanif} and Castillo, {Agnes L.}",
year = "2019",
month = "11",
day = "25",
doi = "10.1016/j.ijpharm.2019.118705",
language = "English",
volume = "571",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

TY - JOUR

T1 - Development, characterization and pharmacokinetics of mupirocin-loaded nanostructured lipid carriers (NLCs) for intravascular administration

AU - Alcantara, Khent P.

AU - Zulfakar, Mohd Hanif

AU - Castillo, Agnes L.

PY - 2019/11/25

Y1 - 2019/11/25

N2 - Mupirocin is a promising broad-spectrum antibiotic that is effective in treating MRSA infections. However, due to its rapid elimination and hydrolysis following injection and high protein binding, current therapeutic use is limited to topical administration. Nanotechnology-driven innovations provide hope for patients and practitioners in overcoming the problem of drug degradation by encapsulation. The objective of this research is to develop and characterize Mupirocin-Loaded Nanostructured Lipid Carriers (M-NLC) for intravascular administration. The MNLC was produced by a combination of high shear homogenization and high pressure homogenization of solid (cetyl palmitate) and liquid (caprylic/caprylic acid) biocompatible lipids in 5 different ratios. The mean particle size, polydispersity index (PDI) and the zeta potential (ZP) of the MNLC formulations were between 99.8 and 235 nm, PDI lower than 0.164, ZP from −25.96 to −19.53 and pH ranging from 6.28–6.49. The MNLC formulation also enhances the anti-bacterial activity of mupirocin. All formulation showed sustained drug release and good physical characteristics for three months storage under 25 °C. It also revealed that the MNLC 1 is safe at 250 mg/kg dose in rats. The MNLC 1 also showed a significant increase in plasma concentration in rabbits following IV administration thus, demonstrating an enhancement on its pharmacokinetic profile as compared to free mupirocin.

AB - Mupirocin is a promising broad-spectrum antibiotic that is effective in treating MRSA infections. However, due to its rapid elimination and hydrolysis following injection and high protein binding, current therapeutic use is limited to topical administration. Nanotechnology-driven innovations provide hope for patients and practitioners in overcoming the problem of drug degradation by encapsulation. The objective of this research is to develop and characterize Mupirocin-Loaded Nanostructured Lipid Carriers (M-NLC) for intravascular administration. The MNLC was produced by a combination of high shear homogenization and high pressure homogenization of solid (cetyl palmitate) and liquid (caprylic/caprylic acid) biocompatible lipids in 5 different ratios. The mean particle size, polydispersity index (PDI) and the zeta potential (ZP) of the MNLC formulations were between 99.8 and 235 nm, PDI lower than 0.164, ZP from −25.96 to −19.53 and pH ranging from 6.28–6.49. The MNLC formulation also enhances the anti-bacterial activity of mupirocin. All formulation showed sustained drug release and good physical characteristics for three months storage under 25 °C. It also revealed that the MNLC 1 is safe at 250 mg/kg dose in rats. The MNLC 1 also showed a significant increase in plasma concentration in rabbits following IV administration thus, demonstrating an enhancement on its pharmacokinetic profile as compared to free mupirocin.

KW - Antimicrobial

KW - Intravenous administration

KW - Mupirocin

KW - Nanomedicine

KW - Nanostructured lipid carriers

UR - http://www.scopus.com/inward/record.url?scp=85073393744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073393744&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2019.118705

DO - 10.1016/j.ijpharm.2019.118705

M3 - Article

C2 - 31536765

AN - SCOPUS:85073393744

VL - 571

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

M1 - 118705

ER -